Bivalirudin in Current Practice: Melius Abundare Quam Deficere?
The optimal antithrombotic therapy for preventing ischemic complications while limiting bleeding risk in patients with acute coronary syndrome (ACS) who are undergoing primary percutaneous coronary intervention (pPCI) remains an area of great controversy (1)[1] The quest for an ideal parenteral
JACC. Cardiovascular interventions